US2005170465A1PendingUtilityA1

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Assignee: GENENTECH INCPriority: Oct 17, 1997Filed: Mar 15, 2005Published: Aug 4, 2005
Est. expiryOct 17, 2017(expired)· nominal 20-yr term from priority
C07K 14/50C07K 14/47Y10S530/866
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid encoding a polypeptide having at least 80% sequence identity to: 
 (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;    (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide;    (c) the amino acid sequence of the polypeptide encoded by the nucleic acid sequence of SEQ ID NO:1;    (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:1; or    (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209385,    wherein said polypeptide inhibits endothelial cell growth.    
     
     
         2 . The isolated nucleic acid of  claim 1  encoding a polypeptide having at least 85% sequence identity to: 
 (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;    (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide;    (c) the amino acid sequence of the polypeptide encoded by the nucleic acid sequence of SEQ ID NO:1;    (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:1; or    (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209385,    wherein said polypeptide inhibits endothelial cell growth.    
     
     
         3 . The isolated nucleic acid of  claim 1  encoding a polypeptide having at least 90% sequence identity to: 
 (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;    (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide;    (c) the amino acid sequence of the polypeptide encoded by the nucleic acid sequence of SEQ ID NO:1;    (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:1; or    (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209385,    wherein said polypeptide inhibits endothelial cell growth.    
     
     
         4 . The isolated nucleic acid of  claim 1  encoding a polypeptide having at least 95% sequence identity to: 
 (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;    (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide;    (c) the amino acid sequence of the polypeptide encoded by the nucleic acid sequence of SEQ ID NO:1;    (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:1; or    (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209385,    wherein said polypeptide inhibits endothelial cell growth.    
     
     
         5 . The isolated nucleic acid of  claim 1  encoding a polypeptide having at least 99% sequence identity to: 
 (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;    (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide;    (c) the amino acid sequence of the polypeptide encoded by the nucleic acid sequence of SEQ ID NO:1;    (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:1; or    (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209385,    wherein said polypeptide inhibits endothelial cell growth.    
     
     
         6 . The isolated nucleic acid of  claim 1  comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:2.  
     
     
         7 . The isolated nucleic acid of  claim 1  comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:2, lacking its associated signal peptide.  
     
     
         8 . The isolated nucleic acid of  claim 1  comprising a nucleic acid sequence of SEQ ID NO:1.  
     
     
         9 . The isolated nucleic acid of  claim 1  comprising the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:1.  
     
     
         10 . The isolated nucleic acid of  claim 1  comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209385.  
     
     
         11 . A vector comprising the nucleic acid of  claim 1 .  
     
     
         12 . The vector of  claim 11 , wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.  
     
     
         13 . An isolated host cell comprising the vector of  claim 11 .  
     
     
         14 . The host cell of  claim 13 , wherein said cell is a CHO cell, an  E. coli  or a yeast cell.

Join the waitlist — get patent alerts

Track US2005170465A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.